特应性多基因风险评分与银屑病患者生物制剂治疗中出现矛盾性湿疹相关
该研究对3,212例银屑病患者(其中88例发生矛盾性湿疹)行GWAS,发现两个全基因组显著SNP:rs192705221(UNC5B附近,P=9.52×10-10)和rs72925168(SLC1A2内,P=1.66×10-9)。三种特应性多基因风险评分均与矛盾性湿疹相关(P<0.05),联合评分关联最强(OR=1.83,95%CI=1.17-2.84,P=0.0078)。将特应性多基因风险评分纳入多变量模型后,AUC由0.671升至0.681-0.686。
要点
- 银屑病患者生物制剂治疗可出现矛盾性湿疹,特应性遗传负荷与之相关。
- 联合特应性多基因风险评分与矛盾性湿疹关联最强(OR=1.83,95%CI=1.17-2.84)。
- 纳入特应性多基因风险评分后模型AUC由0.671升至0.681-0.686。
核心结论
- 特应性遗传负荷与银屑病患者生物制剂治疗中发生的矛盾性湿疹相关,提示共享潜在机制。
- 整合遗传风险可能改善银屑病治疗结局预测模型。
研究设计与样本
- 对3,212例银屑病患者(其中88例发生矛盾性湿疹)行GWAS以识别风险变异。
- 利用已发表GWAS的全基因组显著SNP构建特应性湿疹、一般特应性疾病及两者组合的多基因风险评分,并检验其与矛盾性湿疹的关联。
- 通过曲线下面积评估多基因风险评分对临床风险模型的改善。
主要发现
- 两个领先SNP达到全基因组显著性:rs192705221(UNC5B附近,P=9.52×10-10)和rs72925168(SLC1A2内,P=1.66×10-9)。
- 三种特应性多基因风险评分均与矛盾性湿疹相关(P<0.05)。
- 特应性湿疹与一般特应性疾病组合的多基因风险评分关联最强(OR=1.83,95%CI=1.17-2.84,P=0.0078)。
- 将特应性多基因风险评分纳入包含年龄、性别、特应性背景和银屑病关节炎病史的多变量模型后,AUC由0.671升至0.681-0.686。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biologic therapies for psoriasis can cause paradoxical eczema. The role of genetic factors in its pathogenesis is unknown. To identify risk variants, we conducted a GWAS of 3,212 patients with psoriasis, of whom 88 developed paradoxical eczema. Two lead SNPs reached genome-wide significance (P ≤ 5 × 10-8) for association with paradoxical eczema: rs192705221 (near UNC5B, P = 9.52 × 10-10) and rs72925168 (within SLC1A2, P = 1.66 × 10-9). Genome-wide significant SNPs from published GWAS were used to generate polygenic risk scores (PRSs) for atopic eczema, general atopic disease, or a combination, which were tested for association with paradoxical eczema. Improvement over a clinical risk model was assessed by the area under the curve. All three atopy polygenic risk scores were associated with paradoxical eczema (P < 0.05); polygenic risk score for a combination of atopic eczema and general atopic disease had the strongest association (OR = 1.83, 95% CI = 1.17-2.84, P = 0.0078). Including atopic polygenic risk scores in the multivariable model, which included age, sex, atopic background, and psoriatic arthritis history, increased the area under the curve from 0.671 to 0.681-0.686. Atopic genetic burden is associated with paradoxical eczema occurring in biologic-treated patients with psoriasis, indicating shared underlying mechanisms. Incorporating genetic risk may improve treatment outcome prediction models for psoriasis.
引用
- Al-Janabi A, Eyre S, Foulkes AC, et al. Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics. J Invest Dermatol. 2023. PMID: 36804406. doi:10.1016/j.jid.2023.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。